Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study
Abstract Background Advanced lung adenocarcinoma patients often develop resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), leaving uncertainties regarding subsequent treatment strategies. Although personalized therapy targeting individual acquired resistances (ARs) shows promise, its efficac...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-024-02905-1 |
| _version_ | 1797276016896376832 |
|---|---|
| author | Kan Jiang Lin Wu Xinlong Zheng Yiquan Xu Qian Miao Xiaobin Zheng Longfeng Zhang Cheng Huang Gen Lin |
| author_facet | Kan Jiang Lin Wu Xinlong Zheng Yiquan Xu Qian Miao Xiaobin Zheng Longfeng Zhang Cheng Huang Gen Lin |
| author_sort | Kan Jiang |
| collection | DOAJ |
| description | Abstract Background Advanced lung adenocarcinoma patients often develop resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), leaving uncertainties regarding subsequent treatment strategies. Although personalized therapy targeting individual acquired resistances (ARs) shows promise, its efficacy has not been systematically compared with platinum-containing doublet chemotherapy, a widely accepted treatment after EGFR-TKIs failure. Methods A retrospective dual-center study was conducted involving patients with advanced lung adenocarcinoma and EGFR mutations who developed resistance to EGFR-TKIs between January 2017 and December 2022. Eligible patients were adults aged 18 years or older with an Eastern Cooperative Oncology Group score of 0–1, normal organ function, and no prior chemotherapy. Patients were divided into the chemotherapy group (CG) or personalized therapy group (PG) based on the treatment received after disease progression. The primary endpoints were progression-free survival (PFS) and objective response rate (ORR). Results Of the 144 patients enrolled, there were 53 patients in the PG and 91 patients in the CG. The PG acquired resistance to EGFR-TKIs through the MET amplification (27, 50%) and small cell lung cancer transformation (16, 30%) and 18% of them reported multiple resistance mechanisms. The ORR of the PG was similar to that of the CG (34% vs. 33%, P = 1.0) and the PFS of the PG patients was not statistically different from that of their CG counterparts [4.2 months (95% CI: 3.6–4.8 months) vs. 5.3 months (95% CI: 4.6–6.0 months), P = 0.77]. Conclusions These findings suggest that the therapeutic efficacy of chemotherapy approximates to that of personalized therapy, which signifies that chemotherapy is still a reliable choice for patients who develop resistance to EGFR-TKIs and that further research is awaited to explore the benefit of personalized treatment. |
| first_indexed | 2024-03-07T15:22:17Z |
| format | Article |
| id | doaj.art-cc9c753a114c4fb5838a49022edbbeb2 |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-03-07T15:22:17Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-cc9c753a114c4fb5838a49022edbbeb22024-03-05T17:34:40ZengBMCBMC Pulmonary Medicine1471-24662024-02-012411910.1186/s12890-024-02905-1Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center studyKan Jiang0Lin Wu1Xinlong Zheng2Yiquan Xu3Qian Miao4Xiaobin Zheng5Longfeng Zhang6Cheng Huang7Gen Lin8Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalThe Second Department of Thoracic Oncology, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer HospitalDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalAbstract Background Advanced lung adenocarcinoma patients often develop resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), leaving uncertainties regarding subsequent treatment strategies. Although personalized therapy targeting individual acquired resistances (ARs) shows promise, its efficacy has not been systematically compared with platinum-containing doublet chemotherapy, a widely accepted treatment after EGFR-TKIs failure. Methods A retrospective dual-center study was conducted involving patients with advanced lung adenocarcinoma and EGFR mutations who developed resistance to EGFR-TKIs between January 2017 and December 2022. Eligible patients were adults aged 18 years or older with an Eastern Cooperative Oncology Group score of 0–1, normal organ function, and no prior chemotherapy. Patients were divided into the chemotherapy group (CG) or personalized therapy group (PG) based on the treatment received after disease progression. The primary endpoints were progression-free survival (PFS) and objective response rate (ORR). Results Of the 144 patients enrolled, there were 53 patients in the PG and 91 patients in the CG. The PG acquired resistance to EGFR-TKIs through the MET amplification (27, 50%) and small cell lung cancer transformation (16, 30%) and 18% of them reported multiple resistance mechanisms. The ORR of the PG was similar to that of the CG (34% vs. 33%, P = 1.0) and the PFS of the PG patients was not statistically different from that of their CG counterparts [4.2 months (95% CI: 3.6–4.8 months) vs. 5.3 months (95% CI: 4.6–6.0 months), P = 0.77]. Conclusions These findings suggest that the therapeutic efficacy of chemotherapy approximates to that of personalized therapy, which signifies that chemotherapy is still a reliable choice for patients who develop resistance to EGFR-TKIs and that further research is awaited to explore the benefit of personalized treatment.https://doi.org/10.1186/s12890-024-02905-1Non‐small cell lung cancerEGFR-TKI resistanceChemotherapyPersonalized therapy |
| spellingShingle | Kan Jiang Lin Wu Xinlong Zheng Yiquan Xu Qian Miao Xiaobin Zheng Longfeng Zhang Cheng Huang Gen Lin Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study BMC Pulmonary Medicine Non‐small cell lung cancer EGFR-TKI resistance Chemotherapy Personalized therapy |
| title | Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study |
| title_full | Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study |
| title_fullStr | Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study |
| title_full_unstemmed | Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study |
| title_short | Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study |
| title_sort | chemotherapy versus personalized therapy for egfr mutant lung adenocarcinoma resistance to egfr tyrosine kinase inhibitors a retrospective dual center study |
| topic | Non‐small cell lung cancer EGFR-TKI resistance Chemotherapy Personalized therapy |
| url | https://doi.org/10.1186/s12890-024-02905-1 |
| work_keys_str_mv | AT kanjiang chemotherapyversuspersonalizedtherapyforegfrmutantlungadenocarcinomaresistancetoegfrtyrosinekinaseinhibitorsaretrospectivedualcenterstudy AT linwu chemotherapyversuspersonalizedtherapyforegfrmutantlungadenocarcinomaresistancetoegfrtyrosinekinaseinhibitorsaretrospectivedualcenterstudy AT xinlongzheng chemotherapyversuspersonalizedtherapyforegfrmutantlungadenocarcinomaresistancetoegfrtyrosinekinaseinhibitorsaretrospectivedualcenterstudy AT yiquanxu chemotherapyversuspersonalizedtherapyforegfrmutantlungadenocarcinomaresistancetoegfrtyrosinekinaseinhibitorsaretrospectivedualcenterstudy AT qianmiao chemotherapyversuspersonalizedtherapyforegfrmutantlungadenocarcinomaresistancetoegfrtyrosinekinaseinhibitorsaretrospectivedualcenterstudy AT xiaobinzheng chemotherapyversuspersonalizedtherapyforegfrmutantlungadenocarcinomaresistancetoegfrtyrosinekinaseinhibitorsaretrospectivedualcenterstudy AT longfengzhang chemotherapyversuspersonalizedtherapyforegfrmutantlungadenocarcinomaresistancetoegfrtyrosinekinaseinhibitorsaretrospectivedualcenterstudy AT chenghuang chemotherapyversuspersonalizedtherapyforegfrmutantlungadenocarcinomaresistancetoegfrtyrosinekinaseinhibitorsaretrospectivedualcenterstudy AT genlin chemotherapyversuspersonalizedtherapyforegfrmutantlungadenocarcinomaresistancetoegfrtyrosinekinaseinhibitorsaretrospectivedualcenterstudy |